Influenza virus research reagent: Proteins, antibodies, genes, ELISAs

Influenza (flu) is a respiratory infection in mammals and birds. It is caused by an RNA virus in the family Orthomyxoviridae. The virus is divided into three main types (Influenza A, Influenza B, and Influenza C), which are distinguished by differences in two major internal proteins (hemagglutinin (HA) and neuraminidase (NA)). Influenza virus type A is found in a wide variety of bird and mammal species and can undergo major shifts in immunological properties. Influenza virus type B is largely confined to humans and is an important cause of morbidity. Little is known about Influenza virus type C, which is not an important source of morbidity.

• All are produced in house
• Rapid development of H7N9 HA protein in 12 days
• Rapid preclinical development of H7N9 neutralizing antibody in 6 months

• More than 2500 research reagents: peoteins, antibodies, genes, ELISAs
• More than 60 subtypes: H1-H18, N1-N11, Influenza B
• More than 250 strains: vaccine strains, HPAI strains, high attention strains, new strains
• Ten influenza virus antigens: HA (HA0, HA1, HA2, HA), NA, NP, M1, M2, NS1, NS2, PB1, PB2, PA

• Basic research
• Anti-virus drug development
• virus caccine development
• virus detection research
• anti-virus antibody development

Full length HA protein is always the first choice of antigen for vaccine development. Because of transmembrane domain, it has been very diffcult to manufacture. That is why you can hardly buy HA0. Here is part of full length HA protein produced by Sino Biological Inc. We also can provide CRO service for you.

The antigen-specific B-cell response to the influenza virus hemagglutinin (HA) is critical to the development of universal influenza vaccines. Flu vaccines stimulate B cells in the blood to produce antibodies that neutralize the virus. Mutation (Y98F) to the receptor binding site (RBS) causes HA to bind only those B cells that express HA-specific Abs.

HA titer is as low as 0.2- 0.8 ng/mL for 1% RBC.

Bind with Neu5Aca2-6GalNAca-PAA-biotin or Neu5Aca2-3Galb1-4GlcNAcb-PAA-biotin.

Measured by its ability to cleave a fluorogenic substrate, 2'-(4-Methylumbelliferyl)-α-D-N-acetylneuraminic acid The specific activity can as high as 3000pmol/min/ug.

Neuraminidase mutant from some strains can resist to anti-influenza drug. Those mutant can be applied to new drug development.

Anti HA of H1, H3, H5, H7, H10

H10N8 A/Jiangxi-Donghu/346/2013 pseudovirus infection in 293FT cells. The inhibition is 99.3% under 1 µg/mL antibody (40359-mh001).

Catalog: 11082-R002
The minimum concentration of antibody to stop hemagglutination is 0.16 μg/mL
after being pre-incubated with 1 unit* of H7N9 HA protein(40105-V08B)

Anti-influenza HA : 86001-RM01
• Cross reactivity with HA protein covering over 80 strains
• Binding to H1-H16
Anti-influenza NP: 11675-RP01, 11675-RP02
• Cross reactivity with NP protein among Influenza A
• High sensitivity

The minimum detectable dose of Influenza HA is typically less than 3 pg/mL.

Capture antibody and detection antibody are monoclonal antibodies.